<DOC>
	<DOCNO>NCT02642315</DOCNO>
	<brief_summary>Restless Legs Syndrome ( RLS ) common neurological disorder . Augmentation main complication long-term DA treatment RLS . This study aim examine effect Horizant ( Gabapentin Enacarbil ) Augmentation RLS patient .</brief_summary>
	<brief_title>The Effect Horizant ( Gabapentin Enacarbil ) Augmentation</brief_title>
	<detailed_description>This Open label single arm study . The purpose study demonstrate efficacy Horizant patient RLS exhibit augmentation Dopaminergic therapy . Adult patient ( age 18-85 year ) diagnosis primary RLS ( diagnose study investigator ) augmentation dopaminergic therapy screen participation study . RLS diagnosis make study investigator use International RLS study group criterion . Patients augmentation dopaminergic therapy define NIH 2007 ASRS 5 15 offer participate study . Inclusion exclusion criterion list . The study perform approval Institutional Review Board University Missouri . A total 20 subject enter study period 1 year . Written consent obtain patient . After pre-participation evaluation eligibility , subject select enrol study follow total 6 follow visit ( Days 0 , 30 , 90 , 120 , 180 , 360 ) . Subjects Enrollment period last 12 month . The total duration study 24 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>1 . Adult patient diagnosis RLS one year . 2 . Patients DA therapy 6 month longer . 3 . Patients developed Augmentation ( stable dose DA ) last 3 month longer . 4 . Augmentation severity rating scale 5 15 . 5 . Both male females 6 . Age range = 1885 year Known Hypersensitivity Horizant Gabapentin product Peripheral neuropathy Radiculopathy Peripheral vascular disease Uremia [ abnormal blood urea nitrogen ( BUN ) Creatinine Comprehensive Metabolic Panel ( CMP ) ] Anemia Patients currently pregnant Patients currently take opioids , lithium , antinausea medication ( e.g . metoclopramide ) , dopaminergic antagonist ( e.g . Haloperidol ) , 1st generation antihistamine ( e.g . diphenhydramine , pseudoephedrine ) , antipsychotic medication iron therapy . Subjects impaired decision making capability .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>